Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts
Reuters
Published Jan 09, 2023 08:19AM ET
Updated Jan 09, 2023 08:30AM ET
(Reuters) - The $26,500-per-year price tag for Eisai Co (OTC:ESALY) Ltd and Biogen Inc (NASDAQ:BIIB)'s newly approved Alzheimer's disease drug is slightly above expectations, but should not dent demand for the promising therapy, Wall Street analysts said.
The U.S. health regulator on Friday granted accelerated approval to the drug, Leqembi, and the decision was hailed by patient groups.
The price set by the companies is higher than some analyst estimates of about $20,000.
"As a result of this higher than expected pricing, we think it is reasonable to see peak sales reach $15.2 billion worldwide," BMO analyst Evan Seigerman said in a research note.
However, the price tag is lower than that of Eisai and Biogen's first Alzheimer's disease drug, Aduhelm, which was initially priced at $56,000 annually before the drugmakers halved the price amid controversy over its approval.
"We think this level of pricing is unlikely to generate the intense scrutiny that followed the initial $56K Aduhelm price tag," said Baird analyst Brian Skorney in a research note.
"We don't expect this price to stunt demand for a product (Leqembi) that, in the best case scenario, could slow clinical decline by multiple years."
Still, initial patient access will be limited by several factors including reimbursement restrictions by Medicare, the U.S. government insurance program for Americans aged 65 and older who represent some 90% of individuals likely to be eligible for Leqembi.
Eisai and Biogen said on Saturday the Japanese drugmaker had applied for full approval by the U.S. Food and Drug Administration. Some analysts expect broader coverage by Medicare if the drug is granted full approval.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.